BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17520584)

  • 1. Treatment of advanced head and neck cancer with cetuximab.
    Merlano M; Garrone O
    Int J Biol Markers; 2007; 22(1 Suppl 4):S71-6. PubMed ID: 17520584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of cetuximab in the treatment of squamous cell cancer of the head and neck.
    Burtness B
    Expert Opin Biol Ther; 2005 Aug; 5(8):1085-93. PubMed ID: 16050785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cetuximab and radiotherapy for head and neck cancer.
    Posner MR; Wirth LJ
    N Engl J Med; 2006 Feb; 354(6):634-6. PubMed ID: 16467552
    [No Abstract]   [Full Text] [Related]  

  • 4. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody for treatment of head and neck cancer.
    Herbst RS; Hong WK
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):18-30. PubMed ID: 12422310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More on cetuximab in head and neck cancer.
    Mell LK; Weichselbaum RR
    N Engl J Med; 2007 Nov; 357(21):2201-2; author reply 2202-3. PubMed ID: 18032774
    [No Abstract]   [Full Text] [Related]  

  • 6. Hypofractionated radiotherapy plus cetuximab in locally advanced head and neck cancer.
    Teoh DC; Rodger S; Say J; Hartley A
    Clin Oncol (R Coll Radiol); 2008 Nov; 20(9):717. PubMed ID: 18757187
    [No Abstract]   [Full Text] [Related]  

  • 7. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck.
    Burtness B
    J Clin Oncol; 2005 Aug; 23(24):5440-2. PubMed ID: 16009959
    [No Abstract]   [Full Text] [Related]  

  • 8. Cetuximab in squamous cell head and neck carcinomas.
    Gebbia V; Giuliani F; Valori VM; Agueli R; Colucci G; Maiello E
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi5-7. PubMed ID: 17591832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab plus radiotherapy for head and neck cancer.
    Armstrong JG
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710907
    [No Abstract]   [Full Text] [Related]  

  • 11. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.
    Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK
    N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab plus radiotherapy for head and neck cancer.
    Cengiz M; Yildiz F; Genc M
    N Engl J Med; 2006 May; 354(20):2187; author reply 2187. PubMed ID: 16710908
    [No Abstract]   [Full Text] [Related]  

  • 16. [Recent advances in molecular-targeted drugs in head and neck cancer].
    Tahara M
    Gan To Kagaku Ryoho; 2008 May; 35(5):745-52. PubMed ID: 18487911
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Monoclonal antibodies for the treatment of head and neck cancer].
    Sautois B; Martin M; Demez P; Piret P; Devillers D; Moreau P
    Rev Med Liege; 2009; 64(5-6):284-6. PubMed ID: 19642460
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer.
    Herbst RS; Kim ES; Harari PM
    Expert Opin Biol Ther; 2001 Jul; 1(4):719-32. PubMed ID: 11727507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.